BioRem (BRM) Q3 2025 earnings summary

Executive summary

• Quarterly revenue reached $11.3 million, up 19% sequentially but down 24% year-over-year.

• Net earnings for the quarter were $1.6 million, with EPS of $0.07.

• Record order backlog of $71 million as of September 30, 2025, driven by $17 million in new orders.

• Management anticipates continued growth in order bookings and revenue over the next 12 months.

Financial highlights

• Gross profit for the quarter was $3.2 million (28% margin), down from $5.0 million (33% margin) year-over-year.

• EBITDA for the quarter was $1.7 million, compared to $3.1 million in Q3 2024.

• Year-to-date revenue totaled $25.4 million, down from $28.1 million in the first nine months of 2024.

• Year-to-date net earnings were $1.9 million, compared to $2.9 million in the prior year period.

Outlook and guidance

• Strong order backlog and continued bookings growth expected to drive revenue and earnings growth over the next year.

• Adoption of new products and services is supporting the company’s growth trajectory.